No recent briefing disclosures were available at the time of this report's generation. The analysis below draws on SEC filings, Form 4 insider transaction data, and prevailing macroeconomic indicators as of the generation date of 2026-05-27.
Gilead Sciences reported trailing twelve-month revenue of $29.74 billion as of 2026-03-31, representing year-over-year growth of approximately 4.4% [SEC 10-Q - GILD - 2026-03-31]. Net income over the same period reached $9.22 billion, with a net margin of approximately 31.0% and an operating margin of 34.9%. Gross margin stood at 66.5%. Earnings per share growth on a year-over-year basis was 54.8%, while the price-to-earnings ratio was recorded at 18.32. The company held $7.63 billion in cash against total debt of $23.49 billion, placing market capitalisation at approximately $167.2 billion [SEC 10-Q - GILD - 2026-03-31].
Insider activity is the primary trigger for this report. Over the 30-day period ending 2026-05, 16 transactions were recorded among Gilead insiders, with net direction skewing toward disposal and aggregate net value of approximately -$5.36 million [SEC Form 4 - GILD - 2026-05]. No notable institutional 13F filing data was available within the verified context for inclusion in this report.
The prevailing macroeconomic backdrop features a 10-year US Treasury yield of 4.56% and a 2-year yield of 4.13%, representing a normal yield curve spread of approximately 43 basis points [FRED DGS10] [FRED DGS2]. This yield environment forms part of the broader rate context in which Gilead's debt obligations and cash position are situated.